COMPANY:

PathAI Diagnostics

"Quest Diagnostics...announced that it has completed its previously announced acquisition of PathAI Diagnostics from PathAI, with the goal to accelerate the adoption of AI and digital pathology to improve the diagnosis of cancer and other diseases....In connection with the acquisition, the PathAI Diagnostics state-of-the-art digitized laboratory in Memphis has been rebranded as AmeriPath and will act as the national AI and digital R&D and solutions center supporting Quest's specialty pathology businesses, AmeriPath and Dermpath Diagnostics....In addition, PathAI and Quest have formed separate agreements to further accelerate the adoption of AI and digital pathology based on their strengths and scale."

"Roche announced on Tuesday that it has entered into an agreement with PathAI to develop digital pathology algorithms for companion diagnostics...Under the agreement, PathAI will exclusively work with Roche Tissue Diagnostics to develop artificial intelligence-enabled digital pathology algorithms in the companion diagnostics space, Roche said in a statement."

"PathAI...announced TumorDetect on AISight, PathAI’s digital pathology image management system. TumorDetect is an AI-powered feature of AISight which automates the assessment and quantification of tumor across diverse tissue types."

"PathAI...announced AISightTM supports rendering DICOM Visible Light (VL) Whole Slide Microscopy Image files. AISight is a state-of-the-art, interoperable, intelligent case and image management system to assist pathologists in the review of digitized whole slide images (WSIs) with a comprehensive menu of fully embedded AI solutions."

"PathAI...announced it will present research on advances in artificial intelligence (AI) approaches through three posters at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics on October 11-15 in Boston, Massachusetts, including one poster to be presented in partnership with Flare Therapeutics."

"PathAI...announced the expansion of its BioPharma Laboratory Services. Capitalizing on the 30-year history of delivering high quality pathology services in the PathAI Diagnostics clinical laboratory (formerly known as Poplar Healthcare), PathAI offers biopharma partners a comprehensive, GCP/GCLP compliant histology and digital pathology lab to support prospective clinical trials across oncology, liver, and gastrointestinal indications."

"PathAI...announced the commercial launch of its AISight digital pathology image management system (IMS) for anatomic pathology laboratories. The launch comes at a time when the pathology space is increasingly transitioning to digitally-enabled reads and recognizing the utility of AI and machine learning to enhance quality control, standardize diagnoses, and quantitate biomarkers."

"PathAI...announced the availability of AIM-HER2 Breast Cancer...for research use by clinical laboratories, researchers, and drug developers. AIM-HER2 Breast Cancer delivers automated digital HER2 scoring and is the market’s first algorithm to use additive multiple instance learning (aMIL) heatmaps to visualize the slide features driving the algorithm’s predicted score. AIM-HER2 will be available to biopharma researchers and clinical research lab pathologists on PathAI’s AISight digital pathology platform in both the clinical research lab and clinical trial setting."

"Agilent Technologies Inc...announced a strategic partnership with PathAI, a leading provider of AI-powered research tools and services for pathology, to deliver biopharmaceutical organizations a solution that combines Agilent’s assay development expertise and PathAI’s algorithm development capabilities. By incorporating AI into CDx development, the partnership enables Agilent and PathAI to build integrated solutions with assays and machine learning analysis algorithms....In line with that vision, Agilent also announces a multiyear global distribution agreement with PathAI to distribute both versions of their platform AISight and AISight DX+ along with AIM-PD-L1 NSCLC, an algorithm for PD-L1 quantification in non-small cell lung cancer (NSCLC), to anatomic pathology laboratories. Further, through this partnership, Agilent may also commercialize additional algorithms PathAI launches in the future."

"PathAI will share three posters that highlight uses and advantages of AI-based methods to identify and examine non-small cell lung cancer (NSCLC) and renal cell carcinoma (RCC) specimens. Additionally, PathAI collaborated with Genentech...on two submissions, an oral presentation on H&E-based digital pathology biomarkers in metastatic NSCLC, and a poster presentation on digital PD-L1 tumor cell scoring in NSCLC. PathAI will also be exhibiting in booth 315, where it will showcase the capabilities of its newly launched PathExplore™ product, its AI-powered panel of histopathology features that spatially characterize the tumor microenvironment (TME) with single-cell resolution from H&E slide images."